Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 8/20 | 0.72 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19518818 | 1.00 | NLRP3 (0.72) | NLRP3GSTO1CA2 | |
| SCHEMBL19518827 | 0.94 | NLRP3 (0.69) | NLRP3GSTO1CA2 | |
| SCHEMBL19518904 | 0.93 | NLRP3 (0.62) | NLRP3GSTO1CA2 | |
| SCHEMBL19519038 | 0.91 | NLRP3 (0.78) | NLRP3GSTO1CA2 | |
| SCHEMBL29749516 | 0.88 | NLRP3 (0.64) | NLRP3GSTO1 | |
| SCHEMBL19518903 | 0.88 | NLRP3 (0.64) | NLRP3GSTO1 | |
| SCHEMBL19475056 | 0.87 | NLRP3 (0.55) | NLRP3GSTO1 | |
| SCHEMBL19519060 | 0.87 | NLRP3 (0.55) | NLRP3GSTO1 | |
| SCHEMBL19518817 | 0.85 | NLRP3 (0.55) | NLRP3GSTO1 | |
| SCHEMBL29749313 | 0.85 | NLRP3 (0.68) | NLRP3GSTO1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11597706-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597706-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | NLRP3 2/4885GSTO1 2939/4885CA2 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.